{'fraction_non_alphanumeric': 0.02973240832507433, 'fraction_numerical': 0.006937561942517344, 'mean_word_length': 5.870748299319728, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Use of a BRCA1 peptide validates MS110 as a BRCA1‐specific antibody in immunohistochemistry

has been similarly shown in the testis. In testicular tumours, Zynger et al. have documented uniform GPC3 positivity in most patterns of YST (microcystic, macrocystic, solid, myxomatous, glandular-alveolar, polyvesicular vitelline, papillary, endodermal sinus, and enteric). As previously reported in testicular choriocarcinoma, we observed intense immunoreactivity in malignant syncytiotrophoblast compared with that seen in cytotrophoblast. The utility of GPC3 in differentiating ovarian neoplasms with hepatoid features (e.g. hepatoid YST, oxyphilic clear cell carcinoma, hepatoid carcinoma and steroid cell tumours) from morphologically similar metastases (e.g. hepatocellular carcinoma) remains to be determined. Further studies on the role of this novel biomarker in ovarian development as well as its value in the diagnosis and potentially targeted treatment of ovarian germ cell tumours would be of interest.